Related Experiment Video
Updated: Nov 19, 2025

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
Published on: January 20, 2019
Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development
Fumiya Moribe1, Momoko Nishikori1, Tsuyoshi Takashima2
1Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Background:
SLFN11 has recently been reported to execute cancer cells harboring replicative stress induced by DNA damaging agents. However, the roles of SLFN11 under physiological conditions remain poorly understood. Germinal center B-cells (GCBs) undergo somatic hypermutations and class-switch recombination, which can cause physiological genotoxic stress. Hence, we tested whether SLFN11 expression needs to be suppressed in GCBs during B-cell development.
Objective:
To clarify the expression profile of SLFN11 in different developmental stages of B-cells and B-cell-derived cancers.
Methods:
We analyzed the expression of SLFN11 by mining cell line databases for different stages of normal B-cells and various types of B-cell-derived cancer cell lines. We performed dual immunohistochemical staining for SLFN11 and B-cell specific markers in normal human lymphatic tissues. We tested the effects of two epigenetic modifiers, an EZH2 inhibitor, tazemetostat (EPZ6438) and a histone deacetylase inhibitor, panobinostat (LBH589) on SLFN11 expression in GCB-derived lymphoma cell lines. We also examined the therapeutic efficacy of these drugs in combination with cytosine arabinoside and the effects of SLFN11 on the efficacy of cytosine arabinoside in SLFN11-overexpressing cells.
Results:
SLFN11 mRNA level was found low in both normal GCBs and GCB-DLBCL (GCB like-diffuse large B-cell lymphoma). Immunohistochemical staining showed low SLFN11 expression in GCBs and high SLFN11 expression in plasmablasts and plasmacytes. The EZH2 and HDAC epigenetic modifiers upregulated SLFN11 expression in GCB-derived lymphoma cells and made them more susceptible to cytosine arabinoside. SLFN11 overexpression further sensitized GCB-derived lymphoma cells to cytosine arabinoside.
Conclusions:
The expression of SLFN11 is epigenetically suppressed in normal GCBs and GCB-derived lymphomas. GCB-derived lymphomas with low SLFN11 expression can be treated by the combination of epigenetic modifiers and cytosine arabinoside.
Insights
Schlafen-11 (SLFN11) is epigenetically suppressed in normal germinal center B-cells (GCBs) and GCB-derived lymphomas. Combining epigenetic modifiers with cytosine arabinoside offers a potential treatment for GCB-derived lymphomas with low SLFN11 expression.
Area of Science:
- Cell Biology
- Cancer Biology
- Immunology
Background:
- Schlafen-11 (SLFN11) executes cancer cells under genotoxic stress but its role in physiological conditions is unclear.
- Germinal center B-cells (GCBs) experience genotoxic stress during B-cell development, suggesting a potential role for SLFN11 regulation.
Purpose of the Study:
- To investigate the expression profile of SLFN11 during normal B-cell development and in B-cell-derived cancers.
- To determine the regulatory mechanisms of SLFN11 expression in GCBs.
- To evaluate therapeutic strategies targeting SLFN11 in GCB-derived lymphomas.
Main Methods:
- Analyzed SLFN11 mRNA and protein expression in normal B-cell stages and B-cell cancer cell lines.
- Utilized dual immunohistochemical staining for SLFN11 in human lymphatic tissues.
- Investigated the effect of epigenetic modifiers (EZH2 and HDAC inhibitors) on SLFN11 expression and drug sensitivity in GCB-derived lymphoma cells.
Main Results:
- SLFN11 expression was low in normal GCBs and GCB-like diffuse large B-cell lymphoma (DLBCL).
- Immunohistochemistry revealed low SLFN11 in GCBs, increasing in plasmablasts and plasmacytes.
- Epigenetic modifiers (tazemetostat, panobinostat) upregulated SLFN11 in GCB-derived lymphoma cells, increasing sensitivity to cytosine arabinoside.
Conclusions:
- SLFN11 expression is epigenetically suppressed in normal GCBs and GCB-derived lymphomas.
- GCB-derived lymphomas with low SLFN11 expression are potential candidates for combination therapy with epigenetic modifiers and cytosine arabinoside.
Related Concept Videos
Inheritance of Chromatin Structures
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

